154 related articles for article (PubMed ID: 37976066)
1. Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI Cancer.
Jarnagin JX; Saraf A; Baiev I; Chi G; van Seventer EE; Mojtahed A; Allen JN; Clark JW; Blaszkowsky L; Giantonio BJ; Weekes CD; Klempner SJ; Franses JW; Roeland EJ; Goyal L; Siravegna G; Horick N; Corcoran RB; Nipp RD; Parikh AR
JAMA Netw Open; 2023 Nov; 6(11):e2343512. PubMed ID: 37976066
[TBL] [Abstract][Full Text] [Related]
2. Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer.
van Seventer EE; Fish MG; Fosbenner K; Kanter K; Mojtahed A; Allen JN; Blaszkowsky L; Clark JW; Dubois J; Franses JW; Giantonio BJ; Goyal L; Klempner SJ; Roeland EJ; Ryan DP; Weekes CD; Mulvey T; El-Jawahri A; Horick N; Corcoran RB; Parikh AR; Nipp RD
Cancer; 2021 Feb; 127(4):619-627. PubMed ID: 33170962
[TBL] [Abstract][Full Text] [Related]
3. Associations of patient-reported care satisfaction with symptom burden and healthcare use in hospitalized patients with cancer.
Qian CL; Kaslow-Zieve ER; Azoba CC; Horick N; Wang I; Van Seventer E; Newcomb R; Cashavelly BJ; Jackson VA; Ryan DP; Greer JA; El-Jawahri A; Temel JS; Nipp RD
Support Care Cancer; 2022 May; 30(5):4527-4536. PubMed ID: 35112210
[TBL] [Abstract][Full Text] [Related]
4. Province-Wide Analysis of Patient-Reported Outcomes for Stage IV Non-Small Cell Lung Cancer.
Tjong MC; Doherty M; Tan H; Chan WC; Zhao H; Hallet J; Darling G; Kidane B; Wright FC; Mahar A; Davis LE; Delibasic V; Parmar A; Mittmann N; Coburn NG; Louie AV
Oncologist; 2021 Oct; 26(10):e1800-e1811. PubMed ID: 34216415
[TBL] [Abstract][Full Text] [Related]
5. The utility of abbreviated patient-reported outcomes for predicting survival in early stage colorectal cancer.
Hsu T; Speers CH; Kennecke HF; Cheung WY
Cancer; 2017 May; 123(10):1839-1847. PubMed ID: 28081292
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with patient-reported subjective well-being among advanced lung or non-colonic gastrointestinal cancer patients.
Yennurajalingam S; Kim YJ; Zhang Y; Park J; Arthur J; Chisholm GB; Williams JL; Bruera E
Palliat Support Care; 2018 Feb; 16(1):23-31. PubMed ID: 28264748
[TBL] [Abstract][Full Text] [Related]
7. The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study.
Fiala O; Finek J; Buchler T; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Liska V; Topolcan O
Target Oncol; 2015 Dec; 10(4):549-55. PubMed ID: 25875421
[TBL] [Abstract][Full Text] [Related]
8. Association of Remote Patient-Reported Outcomes and Step Counts With Hospitalization or Death Among Patients With Advanced Cancer Undergoing Chemotherapy: Secondary Analysis of the PROStep Randomized Trial.
Manz CR; Schriver E; Ferrell WJ; Williamson J; Wakim J; Khan N; Kopinsky M; Balachandran M; Chen J; Patel MS; Takvorian SU; Shulman LN; Bekelman JE; Barnett IJ; Parikh RB
J Med Internet Res; 2024 May; 26():e51059. PubMed ID: 38758583
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
10. Survival Prediction and Adjuvant Chemotherapy Based on Tumor Marker for Stage IB Lung Adenocarcinoma.
Wang Y; Zheng D; Chen T; Zhang J; Yao F; Chen H
Ann Thorac Surg; 2020 Mar; 109(3):927-937. PubMed ID: 31614135
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
13. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal patient-reported outcomes and survival among early-stage non-small cell lung cancer patients receiving stereotactic body radiotherapy.
Turner K; Brownstein NC; Thompson Z; El Naqa I; Luo Y; Jim HSL; Rollison DE; Howard R; Zeng D; Rosenberg SA; Perez B; Saltos A; Oswald LB; Gonzalez BD; Islam JY; Tabriz AA; Zhang W; Dilling TJ
Radiother Oncol; 2022 Feb; 167():116-121. PubMed ID: 34953934
[TBL] [Abstract][Full Text] [Related]
15. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
16. Effect of a Symptom Monitoring Intervention for Patients Hospitalized With Advanced Cancer: A Randomized Clinical Trial.
Nipp RD; Horick NK; Qian CL; Knight HP; Kaslow-Zieve ER; Azoba CC; Elyze M; Landay SL; Kay PS; Ryan DP; Jackson VA; Greer JA; El-Jawahri A; Temel JS
JAMA Oncol; 2022 Apr; 8(4):571-578. PubMed ID: 35142814
[TBL] [Abstract][Full Text] [Related]
17. Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer?
Dai WF; Beca J; Guo H; Isaranawatchai W; Schwartz D; Naipaul R; Arias J; Qiao Y; Gavura S; Redmond-Misner R; Ismail Z; Barbera L; Chan K
Cancer Med; 2020 Jan; 9(1):215-224. PubMed ID: 31736256
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported acute fatigue in elderly breast cancer patients treated with and without regional nodal radiation.
Misra S; Lee G; Korzets Y; Wang L; Lau A; Koch CA; Croke J; Helou J
Breast Cancer Res Treat; 2020 Sep; 183(2):391-401. PubMed ID: 32651754
[TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
